RespireRx Pharmaceuticals Inc (RSPI)

[ombowstring]

I e-mailed MV today as follows --


Mark,

There are multiple low and high impacts in the pipeline that should be developed. There are numerous indications that should be actively targeted and clinical studies initiated for. It is blatantly obvious that Cortex with its 11 or so employees is not going to be able to do all this work, not to mention the discovery of new molecules. What would be gained by tackling all these possible projects at a snail’s pace or, rather, delaying them for years?

It seems very evident that it would be better to put all these clinical developments into the hands of a larger company with the financial wherewithal to conduct multiple trials simultaneously. I just don’t see how Cortex might be able to do all this research as a viable, independent company. Therefore, I conclude that the sale of the company is the logical next step to take. Perhaps $.25 – $.50/sh. would be a reasonable price to expect at this stage of the game. Do you think that is doable?

Will there be an ASM this year?

Thanks,
John


His reply --

John,

The issue for Cortex is not being understaffed to perform these studies (much of it can be out-sourced), but our financial wherewithal. Thus, our immediate objectives are to bring in money to allow us to run clinical studies.

As for the sale of the company, this depends on finding companies interested in purchasing Cortex, and offering a price that the Board and shareholders would accept.

We do anticipate holding a shareholder’s meeting later in the year.

Regards,
Mark